Categories: News

Home-based Heart Monitoring Now Available to All Canadians Through Icentia

Canadian company drives at-home cardiac monitoring nationwide during pandemic

QUEBEC CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) — Icentia Inc., a leading Canadian technology company—specialised in cardiac ambulatory monitoring—will be providing a new home-based service nationwide that will enable patients with heart rhythm disorders to have access to an ambulatory cardiac test from the safety of their homes while the pandemic surges on.

Icentia enables at-home tests through its CardioSTAT® device, a Canadian designed and manufactured, proven alternative to traditional Holter monitor tests. Since its introduction in 2015, the CardioSTAT test has become the tool of choice for hundreds of physicians across Canada and the United Kingdom for the detection of heart rhythm disorders. This inventive and life-saving solution is now being implemented nationally for at-home tests in much needed times.

As the pandemic rages on, wait times in the Canadian healthcare system are becoming a serious issue. Backlogs for all procedures, including ECG monitoring, continue to grow. Social distancing and contamination risk requirements have increased the burden on hospitals and clinics, bolstering the demand for home-based tests. “The pandemic is forcing our healthcare system to evolve and adapt. This smart and accurate cardiac monitoring technology is what Canadians need right now to stay safe and keep healthy,” explains Dr. Marko Mrkobrada, Internist, London Health Sciences Centre, London, ON.

This new home-based solution, where no visit to health care facility for hook up or device return is required, promises to lighten the load on medical staff while also increasing safety for all. “We are glad to relieve some of the pressure on our healthcare system and to contribute to more safety through our home-based, patient-initiated tests. CardioSTAT test, which has proven to be easy to use, reliable and safe over the past years, makes even more sense in today’s context,” says Icentia CEO Pierre Paquet.

About CardioSTAT

The CardioSTAT test relies on a unique single-use electrocardiography monitoring device designed to be comfortably worn on the upper chest for up to 14 days. It has the potential to reduce lead times to diagnosis, while providing the patient with a greatly improved experience. Quick and easy to install, it avoids the inconvenience and discomfort caused by multiple skin adhesive electrodes wired to Holter monitors. The result is a highly efficient, yet comfortable and very discrete, wire-free cardiac monitor that does not restrict patients from showering or doing physical activity. Upon complete analysis of the recording by Icentia, results are reviewed by a certified cardiologist before being reported to the patient’s prescribing doctor. For more information, visit cardiostat.com.

About Icentia

Based in Canada, Icentia is a combined medical device and service company. Icentia pioneers innovative solutions for healthcare institutions in the field of medical testing. Icentia aims to help healthcare institutions in becoming more efficient while providing patients with the ease, comfort, peace of mind and safety of reliable at-home medical monitoring through technological advances. For more information, visit icentia.com.

CONTACT: Icentia Inc.
1 800 431 9148
info@icentia.com 

Staff

Recent Posts

Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

2 hours ago

FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers

NEW CANAAN, Conn., Dec. 22, 2025 /PRNewswire/ -- FlyteHealth, a national leader in integrated cardio-kidney-metabolic care,…

2 hours ago

10 Days, 10 Ways to Spend FSA (Flexible Spending Account) Funds Before the December 31 Use-It-or-Lose-It Deadline, from FSA Store®

The clock is ticking on 2025 FSA funds, and as the use-it-or-lose-it deadline approaches, FSA…

2 hours ago

TraceLink Wins 2025 Merit Award — Recognized for Healthcare Innovation for the Third Consecutive Year

TraceLink has been named a winner of the 2025 Merit Awards for Healthcare Innovation, marking…

2 hours ago

NUCALM CELEBRATES RECORD-BREAKING DECEMBER WITH OVER 2 BILLION MINUTES USED AND LARGEST LIVE EVENT ACTIVATION EVER

Tony Robbins' "Date with Destiny" Event Drives Unprecedented Engagement with NuCalm TechnologyPALM BEACH, Fla., Dec.…

2 hours ago

Point-of-Care Is Just the Beginning: Doceree 360 Report Maps Three Strategic Imperatives for HCP Engagement Across All Digital Touchpoints

New Annual Report Reveals Opportunity for Pharma Marketers to Reach Physicians Throughout Entire Decision-Making Journey—From Learning…

2 hours ago